proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

Huge Decreases in LDL Cholesterol With Alirocumab: ODYSSEY

Michael O'Riordan

August 31, 2014

RELATED LINKS

• Alirocumab Safely Lowers LDL Cholesterol in Nine Trials
• UPDATED: PCSK9 Inhibitor Evolocumab Passes Test in Two Phase 3 Studies
• PCSK9 Inhibitor Beats Ezetimibe for LDL Lowering

BARCELONA, SPAIN — Treatment with alirocumab(Sanofi/Regeneron Pharmaceuticals), an investigational proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in significant reductions in LDL cholesterol in various groups of patients who received the drug, including individuals at high risk for cardiovascular events currently taking a maximally tolerated statin dose.

In one analysis of the ODYSSEY Long-Term Study , a study consisting of 2341 patients at high risk for cardiovascular events, investigators conducted a post hoc analysis to investigate the effect of alirocumab on major cardiovascular events, the same end point being tested in the major morbidity and mortality ODYSSEY OUTCOMES study. After 65 weeks of treatment, the results suggested alirocumab significantly reduced the risk of major events compared with those who received placebo and a maximally tolerated statin./.../